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case report
Frasier syndrome: four new cases 
with unusual presentations 
Síndrome de Frasier: quatro novos casos com apresentação atípica
Mara Sanches Guaragna1, Anna Cristina Gervásio de Britto Lutaif2, Viviane 
Barros Bittencourt3, Cristiane Santos Cruz Piveta1,4, Fernanda Caroline Soardi1, 
Luiz Claudio Gonçalves Castro5, Vera Maria Santoro Belangero2, Andréa 
Trevas Maciel-Guerra6, Gil Guerra-Junior4,7, Maricilda Palandi De Mello1 
SUMMARY
Frasier syndrome (FS) is characterized by gonadal dysgenesis and nephropathy. It is caused by 
specific mutations in the Wilms’ tumor suppressor gene (WT1) located in 11p23. Patients with 
the 46,XY karyotype present normal female genitalia with streak gonads, and have higher risk of 
gonadal tumor, mainly, gonadoblastoma. Therefore, elective bilateral gonadectomy is indicated. 
Nephropathy in FS consists in nephrotic syndrome (NS) with proteinuria that begins early in 
childhood and progressively increases with age, mainly due to nonspecific focal and segmental 
glomerular sclerosis (FSGS). Patients are generally unresponsive to steroid and immunosup-
pressive therapies, and will develop end-stage renal failure (ESRF) during the second or third de-
cade of life. We report here four cases of FS diagnosis after identification of WT1 mutations. Case 
1 was part of a large cohort of patients diagnosed with steroid-resistant nephrotic syndrome, in 
whom the screening for mutations within WT1 8-9 hotspot fragment identified the IVS9+5G>A 
mutation. Beside FS, this patient showed unusual characteristics, such as urinary malformation 
(horseshoe kidney), and bilateral dysgerminoma. Cases 2 and 3, also bearing the IVS9+5G>A 
mutation, and case 4, with IVS9+1G>A mutation, were studied due to FSGS and/or delayed pu-
berty; additionally, patients 2 and 4 developed bilateral gonadal tumors. Since the great majority 
of FS patients have normal female external genitalia, sex reversal is not suspected before they 
present delayed puberty and/or primary amenorrhea. Therefore, molecular screening of WT1 
gene is very important to confirm the FS diagnosis. Arq Bras Endocrinol Metab. 2012;56(8):525-32
SUMÁRIO
A síndrome de Frasier (SF), caracterizada por disgenesia gonadal e nefropatia, é causada por mu-
tações específicas no gene supressor do tumor de Wilms (WT1) localizado em 11p23. Pacientes 
com cariótipo 46,XY apresentam genitália feminina normal com gônadas disgenéticas e alto risco 
de tumor gonadal, principalmente o gonadoblastoma. Por isso, a gonadectomia bilateral eletiva 
está indicada. A nefropatia na SF consiste de síndrome nefrótica com proteinúria que se inicia 
na infância e aumenta progressivamente com a idade, principalmente devido à glomeruloescle-
rose focal e segmentar (GESF). Esses pacientes não respondem ao tratamento com esteroides 
e imunossupressores e desenvolverão insuficiência renal crônica durante a segunda ou terceira 
década de vida. Neste trabalho, são relatados quatro casos de SF cujo diagnóstico foi definido 
após o rastreamento molecular do gene WT1. O caso 1 faz parte de um grande grupo de pacientes 
que tiveram diagnóstico de síndrome nefrótica corticorresistente e no qual o rastreamento de 
mutações no fragmento 8-9 do gene WT1 identificou a mutação IVS9+5G>A. Além da SF, essa pa-
ciente apresentou características incomuns, tais como malformação urinária (rins em ferradura) e 
disgerminoma bilateral. Os casos 2 e 3 também apresentaram a mutação IVS9+5G>A, e, no caso 
4, foi identificada a mutação IVS9+1G>A, sendo que esses três casos foram encaminhados para 
estudo molecular em decorrência de GESF e/ou atraso no desenvolvimento puberal. Além disso, 
as pacientes 2 e 4 desenvolveram tumor gonadal bilateral. Visto que a maioria dos pacientes com 
SF apresenta genitália externa feminina, não há suspeita de sexo reverso até apresentarem atraso 
puberal e/ou amenorreia primária. Portanto, o rastreamento molecular do gene WT1 é de funda-
mental importância para se confirmar o diagnóstico de SF. Arq Bras Endocrinol Metab. 2012;56(8):525-32
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INTRODUCTION
Frasier syndrome (FS, OMIM #136680) is a rare disorder of sex development defined by 46,XY 
karyotype, gonadal dysgenesis, and progressive glo-
merulopathy (1). The great majority of cases present 
normal female internal and external genitalia, streak 
gonads, and high risk of developing gonadoblastoma. 
In addition, a case with 46,XX karyotype and normal 
ovaries has also been described (2). Glomerular symp-
toms in FS patients consist on childhood proteinuria 
and nephrotic syndrome (NS), characterized by focal 
and segmental glomerular sclerosis (FSGS). Patients 
are frequently unresponsive to treatment with steroids 
and immunosuppressors, and progress to end-stage re-
nal failure in adolescence or early adulthood (3,4). 
FS and Denys-Drash syndrome (DDS, OMIM 
#194080) are two overlapping diseases, characterized by 
nephrotic syndrome associated with either diffuse me-
sangial sclerosis in DDS, or focal segmental glomerular 
sclerosis in FS, genitourinary defects, and higher risk of 
developing tumors, such as Wilms’ tumor in DDS, and 
gonadal tumor in both DDS and FS (5,6). Although 
not frequently observed in FS patients, Wilms’ tumor 
has been reported (7).
Different mutations in the Wilms’ tumor suppressor 
gene (WT1, OMIM *607102) located in 11p23 may 
cause either DDS or FS. WT1 gene contains ten exons 
that encode a transcription factor with four zinc fin-
ger motifs, essential for both renal and genital normal 
development. Two main alternative splicings produce 
four WT1 isoforms: two of them differ from each other 
by the presence or absence of 17 amino acids encoded 
by exon 5; and the other two are distinguished by the 
inclusion or exclusion of the amino acids lysine, threo-
nine, and serine (KTS) between zinc fingers 3 and 4 as a 
result of two active splice donor sites in intron 9 (Figure 
1). The normal WT1 isoform ratio is 2KTS(+):1KTS(-). 
This ratio is considered to be temporally and spatially 
stable during development and throughout life (8). In 
general, FS patients carry mutations that affect the 2:1 
ratio for WT1 KTS isoforms located in the intron 9 
donor splice site, while mutations in patients with DDS 
are mostly missense (80%) within zinc fingers 2 and 3 
comprised by exons 8 and 9 (8). Based on those data, 
exons 8, 9, and intron 9 are considered hotspots for 
mutations in both conditions. Therefore, the sequence 
spanning from exon 8 to intron 9 is usually called WT1 
8-9 hotspot fragment.
Figure 1. Representation of the WT1 exons and introns showing splicing 
from 1 to 9 to form WT1 isoform with exon 5 (dashed grey lines above 
boxes) and three alternative splicing events (dashed black lines below 
boxes) leading to isoforms without exon 5 (-E5), and either +KTS or -KTS. 
The nucleotide sequence coding for KTS is denoted. Frasier syndrome 
results from G>A nucleotide change at +1 (case 4) and +5 (cases 1, 2, 3) 
intronic position after KTS coding sequence. Inactivation of intron 9 splice 
donor site to form +KTS isoform is the result of these mutations. Exon 
numbers are presented below boxes. ATG and TGA correspond to 
translation start and stop codons, respectively.
The diagnosis of FS is often suspected upon evalu-
ation of delayed puberty or primary amenorrhea in pa-
tients with nephrotic syndrome, focal segmental glo-
merular sclerosis, or end stage renal failure awaiting 
kidney transplantation, and it is confirmed by demon-
strating mutations in the WT1 gene.  
Here, we report four new cases of FS in which 
IVS9+1G>A and IVS9+5G>A WT1 mutations were 
identified. Case 1 was part of a large cohort of patients 
that had the diagnosis of steroid-resistant nephrotic 
syndrome (SRNS), in whom the screening for muta-
tions within WT1 8-9 hotspot fragment identified the 
IVS9+5G>A mutation. Beside FS, this patient showed 
unusual characteristics, such as urinary malformation 
and bilateral dysgerminoma. Cases 2 and 3, also bearing 
IVS9+5G>A mutation, and case 4, with IVS9+1G>A 
mutation, were studied due to FSGS and/or delayed 
puberty; additionally, patients 2 and 4 had developed 
bilateral gonadal tumor. 
MATERIALS AND METHODS
Genomic DNA extraction from peripheral blood leu-
kocytes was performed by standard techniques (9). The 
WT1 8-9 hotspot fragment was amplified by PCR with 
specific primers (exon 8: forward 5’-TAC CCT AAC 
AAG CTC CAG GG-3’; reverse 5’-GAG AAT CAT 
GAA ATC AAC CCT AG-3’ and exon 9: forward 5’-
TGA GGC AGA TGC AGA CAT TG-3’; reverse -5’-
TCT CTC AAC TGA GTC TAA ACC TTA G-3’). The 
final volume for all reactions was 50 mL and contained 
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USA), 1.5 mM MgCl2, 2 mM of each dNTP, 20 pmol 
of each primer, 300-500 ng genomic DNA templates, 
and 2 units of recombinant Taq DNA polymerase (In-
vitrogen). After a first denaturation step (5 min, 94°C), 
the cycling profile was: 94°C, 1 min; 54°C, 1 min; 
72°C, 2 min (30 cycles), followed by 5 min at 72°C 
(final extension). The size of the PCR products was de-
termined in 1% agarose gel electrophoresis stained with 
ethidium bromide. Before sequencing, purification of 
PCR products was performed using the Wizard® SV 
Gel and PCR clean-up system (Promega, Madison, WI, 
USA). Further direct sequencing using ABI PRISM 
Big Dye Terminator v3.1 Cycle Sequencing Kit (ABI 
PRISM/PE Biosystems, Foster City, CA, USA) was 
carried out in four reactions, using sense and antisense 
primers. The sequences were obtained in an automat-
ic sequencer ABI PRISM 3130 DNA Analyzer (ABI 
PRISM/PE Biosystems). The free softwares Chromas 
Pro v.1.5 and CLC Sequence Viewer v.6.6.2 were used 
to analyze and compare sequences with the published 
WT1 (ENSG00000184937) sequence at Ensembl da-
tabase (www.ensembl.org). Y-chromosome sequence 
analysis was conducted by PCR and nested-PCR with 
primers for SRY gene, TSPY gene and Y-centromeric 
region DYZ3, as described elsewhere (10). After PCR 
amplification, reaction products (10 µl) were submitted 
to 2% agarose gel electrophoresis stained with ethidium 
bromide and using a molecular weight marker. Each 
PCR reaction contained normal female and male con-
trols (data not shown). Chromosome analyses were 
performed on peripheral blood lymphocytes using 




A 7-year-old female child was included in a study in 
which the screening for mutations within  WT1 8-9 
hotspot fragment was being performed in a group of 
patients with steroid-resistant nephrotic syndrome 
(SRNS). She had been followed up in the Pediatric 
Nephrology Outpatient Clinic from Clinical Hospital 
of State University of Campinas (Unicamp) – Brazil, 
since she was 5.1 years old, due to persistent edema 
and proteinuria. She was initially treated with predni-
sone 2 mg/kg/day for 8 weeks. After that, she received 
cyclophosphamide and prednisone during another pe-
riod of 8 weeks, when an increment in albuminemia 
and a decrease in proteinuria were observed. However, 
the condition relapsed one week after the withdrawal 
of cyclophosphamide. Serum cholesterol level was very 
high, there was no hematuria, and renal function was 
normal. Ultrasound showed horseshoe kidney, uretro-
cystography did not show reflux, and DMSA scintigra-
phy revealed mild bilateral decrease of tubular function, 
without scars. As she remained without remission and 
a kidney biopsy was not indicated, she received cyclo-
sporine A associated with angiotensin receptor blocker, 
statin, vitamin D, and cephalexin for urinary infection 
prophylaxis during 18 months. There was a positive 
clinical response with those therapies, with stabilization 
of albumin and cholesterol levels and renal function. Af-
ter this period, there was an increase in α-microglobulin 
levels suggesting tubular lesion. Therefore, cyclospo-
rine A was suspended. The IVS9+5G>A WT1 hetero-
zygous mutation was identified (Figure 2). The search 
for Y-chromosome sequences by PCR was positive, and 
the 46,XY chromosomal constitution was confirmed by 
karyotyping (data not shown). Because of the increased 
risk of gonadoblastoma in such cases, gonadectomy 
was performed. On histopathology, there was bilateral 
dysgerminoma (Figures 3A and 3B). Thirty months af-
ter surgery, neither abdominal and thoracic computed 
tomography (CT) nor pelvic magnetic resonance im-
aging (MRI) showed postoperative spreading or re-
emergence of the tumor. At the age of 10 years, she 
presented ESRF, which led to peritoneal dialysis during 
one month before she received kidney transplantation.
Figure 2. Electropherograms of WT1 exon 9 and intron 9 bordering 
sequences. The splice sites for –KTS and +KTS isoforms are shown in red 
and dark blue, respectively. Arrows show the IVS9+5G>A heterozygous 
mutation in cases 1, 2, 3, and the IVS9+1G>A heterozygous mutation in 
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Figure 3. Gonadal morphology of case 1 (A: right dysgerminoma, H&E, 100x; B: left dysgerminoma, H&E, 400x); case 2 (C: dysgenetic gonad with 
gonadoblastoma, macroscopy; D: gonadoblastoma with dysgerminoma, macroscopy); and case 4 (E: gonadoblastoma and dysgerminoma, H&E, 40x; 
F: H&E, 100x). 
Case 2 
A female child was seen at the Pediatric Nephrology Out-
patient Clinic from Santo Antonio Children’s Hospital of 
Porto Alegre – Brazil. She had been conceived by artifi-
cial insemination and was born with 32 weeks of gesta-
tion. She was a healthy child, and was in the 75th growth 
percentile until the age of 8 years and 9 months. Then, 
she began to lose weight and to show delayed growth. 
Upon investigation, renal dysfunction was diagnosed 
and renal biopsy revealed FSGS at the age of 9 years. 
She did not respond to steroids and cyclosporine. At the 
age of 10 years and 10 months, she was submitted to 
bilateral nephrectomy and received a living donor kid-
ney transplant. Tacrolimus, sodium micophenolate, and 
prednisone treatment were started then, and have been 
maintained up to the present moment. Before starting 
immunosuppressive therapy, gonadotropin levels were 
evaluated, and were in the normal range for prepuber-
tal females. When she was 11 years old, she developed 
spontaneous puberty, reaching breast development Tan-
ner stage 3 and pubic hair Tanner stage 3 at the age of 
13 years; however, menarche was absent. At this time, a 
new hormone evaluation showed low inhibin levels (< 32 
pg/mL), and hypergonadotrophic hypogonadism (LH 
= 76 IU/L and FSH = 195 IU/L). Pelvic ultrasonog-
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and a long (~ 12 cm) and a small (~ 1 cm) structure at 
the left and right gonad topography, respectively; lymph 
nodes were not visualized. The karyotype was 46,XY and 
a search for Y-chromosome sequences was positive (data 
not shown). WT1 genotyping indicated heterozygosis for 
the IVS9+5G>A mutation (Figure 2). Tumoral markers, 
such as alpha-fetoprotein and human chorionic gonado-
tropin were elevated, and bilateral gonadectomy was 
performed at 13 years of age. Histopathology revealed 
bilateral gonadoblastoma associated with dysgerminona 
in the left gonad (Figures 3C and 3D). Oncologists and 
nephrologists decided to maintain her under conserva-
tive follow-up, without chemotherapy or changes in the 
immunosuppressant treatment. After 17 months of sur-
gery, tumoral markers were negative, and abdominal and 
thoracic computed tomography (CT) and pelvic magnet-
ic resonance imaging (MRI) did not show spreading or 
reemergence of the tumor. Nowadays, at 15 years of age, 
she receives estrogen and progesterone therapy, is in Tan-
ner stage B5P5, presents cyclical menses, and her growth 
remains within the 75th percentile. Renal and hepatic bio-
chemical evaluations are within the normal range.
Case 3 
Patient 3 was also followed up in Pediatric Nephrology 
Outpatient Clinic from Santo Antonio Children’s Hospi-
tal of Porto Alegre – Brazil. At the age of 4 years, she de-
veloped SRNS. Biopsy showed FSGS, and the patient did 
not respond to a course of cyclosporine. When she was 
9 years old, she developed ESRF, leading to renal trans-
plantation at age of 10. With the age of 14 years, she had 
not initiated breast development, indicating delayed pu-
berty associated with primary amenorrhea, slight clitoro-
megaly, and hypergonadotrophic hypogonadism (LH = 
97 IU/L and FSH = 192 IU/L). Karyotype was 46,XY. 
A search for Y-chromosome sequences was positive (data 
not shown). Upon WT1 8-9 hotspot fragment sequenc-
ing, she presented the IVS9+5G>A heterozygous muta-
tion (Figure 2). At age of 15 years, bilateral gonadectomy 
was performed and no tumor was identified (data not 
shown). Nowadays, she is initiating sex hormone replace-
ment and maintains normal graft function. Immunossu-
pression treatment has not been changed. 
Case 4 
This female child was also followed up at Pediat-
ric Nephrology Outpatient Clinic from Santo Anto-
nio Children’s Hospital of Porto Alegre – Brazil. She 
was diagnosed with ESRF at the age of 9 years. She 
started dialysis immediately after the diagnosis. The 
etiology of renal failure was attributed to a history of 
recurrent urinary infections and vesicoureteral reflux. 
Additionally, a detailed clinical history revealed recur-
rent edema episodes, which had not been investigated 
before. At the age of 10, the patient underwent renal 
transplantation with good initial outcome. After the 
third year of transplantation, worsening of graft func-
tion was observed, with signs of mild chronic allograft 
nephropathy. Biopsy was not performed. The patient 
started puberty spontaneously at 11 years old, reach-
ing breast development Tanner stage 4 and pubic hair 
Tanner stage 4 at 14 years old, without menstruation. 
At that time, she presented  hypergonadotrophic hy-
pogonadism (LH = 76 IU/L and FSH = 92 IU/L) 
and evident clitoromegaly. Karyotyping was performed 
resulting in 46,XY, and a search for Y-chromosome se-
quences was positive (data not shown). The analysis of 
WT1 8-9 hotspot fragment revealed the IVS9+1G>A 
heterozygous mutation (Fi gure 2). Bilateral gonadec-
tomy was performed showing gonadoblastoma associ-
ated with bilateral dysgerminoma (Figures 3E and 3F). 
Abdominal and thoracic computed tomography (CT) 
and pelvic magnetic resonance imaging (MRI) indi-
cated no spreading or reemergence of the tumor to 
date, but the levels of human chorionic gonadotropin 
did not diminish. Therefore, chemotherapy was started 
and immunosuppression with tacrolimus+mycophenol
ate+prednisone was replaced by sirolimus+prednisone 
treatment. After 30 months of follow-up, she did not 
present any signs of metastases. She is receiving hor-
monal replacement with normal pubertal development 
and menstruation. Graft function has decreased after 
chemoterapy and decreased immunossupression. Her 
creatinine level is 2.4 mg/dL.
DISCUSSION
In the present study, we analyzed the WT1 8-9 hotspot 
fragment of four patients with FS. Their follow-up, tu-
mor characteristics and molecular data are summarized 
in table 1. Heterozygous mutations in the second al-
ternative splice donor site of intron 9 were found in all 
cases. The IVS9+5G>A mutation, identified in cases 1, 
2 and 3, has already been described, and is well cor-
related with FS (8,11). The IVS9+1G>A mutation, 
identified in case 4, was described for the first time in 
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Associated conditions WT1 mutation
Diagnosis Treatment




1 10.5 5.1 - 10.0 10.1 7.3 - - Dys Dys Bilateral horseshoe kidneys IVS9+5G>A
2 15.1 - 9.0 8.8 10.8 13.0 11.0 (B3P3) 13.0 Gon Gon + Dys - IVS9+5G>A
3 15.3 4.0 4.3 9.0 10.0 14.0 - 14.3 - - Clitoromegaly IVS9+5G>A





B: breast development; Dys: dysgerminoma; ESRF: end-stage of renal failure; FSGS: focal and segmental glomerulosclerosis; Gon: gonadoblastoma; GOx: gonadectomy; KTx: kidney transplantation; 
NS: nephrotic syndrome; P: pubic hair development.
mutations affect the KTS(+) isoform production and 
impair the 2:1 ratio for KTS(+) and KTS(-) isoforms, 
respectively, which are important for the normal devel-
opment of the glomerular podocytes and for male sex 
determination (13).
Type II germline cell tumors of the testes and dys-
genetic gonads are, by far, the most frequently occur-
ring and feared tumors in 46,XY DSD patients. Carci-
noma in situ is virtually the only precursor lesion found 
in patients with undervirilization syndromes arising in 
well-differentiated testicular tissue. Nevertheless, nearly 
all in situ neoplastic lesions in patients with dysgenetic 
gonads are gonadoblastomas, either overgrown or not 
by dysgerminoma. If the gonad is considered a testis, 
invasive type II germline cell tumors found in of 46,XY 
DSD patients are seminomas, whereas if the gonad is 
dysgenetic or considered an ovary, the tumor is a dys-
germinoma (14,15). 
According to Lee and cols. (16) in the Consensus 
Statement on Management of Intersex Disorders, FS 
has the highest risk (~60%) of develop germline cell 
tumors, the great majority being gonadoblastomas. In 
this study, three out of four patients presented bilateral 
tumors. Case 1 had isolated dysgerminomas in the two 
gonads; case 2 had an isolated gonadoblastoma in the 
right gonad, and a dysgerminoma associated with go-
nadoblastoma in the left gonad; and case 4 had a dys-
germinoma associated with gonadoblastoma in both 
gonads. In the review by Joki-Erkkilä and cols. (17) 
published in 2002, only three FS patients were report-
ed as presenting dysgerminomas (3,17,18). After that, 
three cases were reported: a 17-year-old FS patient with 
a non-informed WT1 heterozygous mutation with go-
nadoblastoma and dysgerminoma in each gonad (19); 
an 11-year-old FS patient with IVS9+5G>A WT1 het-
erozygous mutation, with bilateral dysgerminoma and 
a pilocytic astrocytoma (20); and a 13-year-old FS pa-
tient with IVS9+4C>T WT1 heterozygous mutation, 
with unilateral dysgerminoma, totalizing six FS cases 
with dysgerminoma to date. 
Therefore, patients 1, 2, and 4 presented here are 
novel cases of young patients with FS and bilateral 
gonadoblastoma associated with dysgerminoma and 
submitted to bilateral gonadectomy, with neither re-
surgence nor metastasis appearing during follow-up. 
Generally, if the presence of metastasis is observed, 
chemotherapy should be the first-line of treatment for 
dysgerminoma, but it is important to have in mind that 
there is no specific tumor marker, that chemotherapy 
may worsen renal function, and that kidney transplan-
tation may not be carried out at the same time (21). 
Because of this, it is advisable that kidney transplanta-
tion should not be done until two years after gonadec-
tomy in FS (21). Unfortunately, two patients described 
here (cases 2 and 4) had kidney transplantation before 
gonadectomy. However, this did not cause any negative 
consequences. Since patient 2 developed donor specific 
antibodies, it was decided to decrease immunossupres-
sive treatment. Since there were no signs of metastases 
and human chorionic gonadotropin level normalized 
promptly, chemotherapy was also not carried out. It is 
not possible to determine if immunossupression due to 
kidney transplantation in cases 2 and 4 has contributed 
to the appearance of the malignant tumor, or if it would 
have occurred even in the absence of immunossupres-
sion, but these patients were submitted to unnecessary 
risk of metastases.
To our knowledge, this is the first report of a FS pa-
tient with a horseshoe kidney, which is one of the most 
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tem (22). It is frequently associated with anomalies of 
other systems in which genetic factors may play a com-
mon etiological role, including musculoskeletal, car-
diovascular, and gastrointestinal systems, as well as in 
certain neurological conditions (23). The occurrence 
of glomerulonephritis in horseshoe kidney has already 
been reported (24-27), with focal and segmental glo-
merulosclerosis described in two cases (25,27). 
Since the great majority of FS patients have normal 
female external genitalia, sex reversal is not suspected 
until later in life, when these patients report delayed 
puberty and/or primary amenorrhea. In general, de-
layed puberty in patients with chronic disease, like re-
nal disease, is due to hypogonadotrophic hypogonad-
ism, but in FS patients it is due to hypergonadotrophic 
hypogonadism, since they present dysgenetic gonads. 
Therefore, evaluation of LH, and mainly FSH, is man-
datory in all patients with chronic renal disease without 
normal puberty, and if those levels are elevated, karyo-
typing should be performed (28), since XY patients 
have been reported to have high risk of gonadal tumors 
(14-16). It is interesting to observe that, although 
cases 2 and 4 have begun puberty spontaneously, they 
did not reach complete puberty with menstruation, and 
that cases 3 and 4 presented clitoromegaly. Joki-Erkkilä 
and cols. (17) showed that almost 75% of the FS pa-
tients with gonadal tumors (gonadoblastoma and/or 
dysgerminoma) developed spontaneous puberty. These 
authors found positivity for inhibin, estrogen, and pro-
gesterone receptors in gonadal stroma and gonadal 
tumors of FS patients, and they speculated that dysge-
netic gonads with or without tumors could be targets 
for hormonal activity.   
This far, it is also important to note that if patients 
with SRNS and WT1 mutations remain unrecognized, 
they may be treated with potentially systemic toxic drugs, 
without any evidence of benefit. Therefore, this paper 
and other recent reports emphasize the importance of 
screening patients with SRNS for WT1 mutations (4,29). 
Finally, this study highlights that FS phenotypes 
may be variable and sometimes unexpected. Impor-
tantly, when FS is suspected, molecular evaluation must 
be performed, once only the identification of WT1 mu-
tations supports definitive diagnosis, which is essential 
for establishing the most adequate clinical and surgical 
approaches and management of those patients. In con-
clusion, if all those issues are considered, unnecessary 
and ineffective treatments, as well as postponing the 
right moment for gonadectomy, would be avoided. 
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